ArticleFrontiers in medicine2025
Global, regional, and national burden of pulmonary arterial hypertension in adults aged ≥60 years from 1990-2021: SDI-stratified trend analysis and projections to 2050.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pulmonary arterial hypertension (PAH), a progressive and life-threatening condition, has significant implications for public health, particularly in the aging population. This study provides a comprehensive analysis of PAH in individuals aged 60 years and older from 1990 to 2021, utilizing data from the Global Burden of Disease (GBD) 2021 study, which encompasses 204 countries and territories. Methods: We tracked PAH trends (1990-2021) with three metrics: the annual percentage change (APC) from joinpoint, the average APC (AAPC) across segments, and the estimated APC (EAPC) from the log-linear model. APC captures year-by-year shifts; AAPC summarises the whole period; EAPC gives a single long-term slope. Significance set at 95% CI excluding zero. For 2022-2050 we used the Bayesian age-period-cohort (BAPC) model, which extends these time-component ideas into future projections. Results: Between 1990 and 2021, the number of new cases increased by 130%, deaths by 130%, and disability-adjusted life years (DALYs) increased by 100%. In 2021, there were 15,622 new cases, 15,443 deaths, and 248,064 DALYs globally. The incidence rate rose from 1.447 to 1.66 per 100,000 population. Looking ahead to 2050, we project the number of new cases to reach 31383 (95% CI: 17604.40, 45162.56), an incidence rate of 1.46 per 100,000, approximately 20,687 deaths, and 302,760 DALYs. In addition, Zambia recorded the highest incidence rate, while China had the largest total number of cases. The middle Sociodemographic Index (SDI) region bore the highest disease burden, highlighting disparities in the global distribution of PAH. Conclusion: These findings underscore the escalating burden of PAH among the elderly and emphasize the urgent need for targeted public health strategies to address this growing challenge. Our study highlights the importance of continued surveillance and the development of interventions to mitigate the impact of PAH on aging populations worldwide.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.